Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lyra Therapeutics Completes Enrollment in Phase 3 Trial for Chronic Rhinosinusitis
Details : LYR-210 (mometasone furoate) is a glucocorticoid receptor agonist. It is being evaluated as an anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis.
Product Name : LYR-210
Product Type : Steroid
Upfront Cash : Inapplicable
October 15, 2024
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210
Details : LYR-210 (mometasone furoate) is a glucocorticoid receptor agonist. It is being evaluated as an anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis.
Product Name : LYR-210
Product Type : Steroid
Upfront Cash : Inapplicable
June 05, 2024
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYR-220 (mometasone furoate) is a bioresorbable, polymetric matrix that is designed to deliver six months of continuous anti-inflammatory medication (7500µg MF) to the sinonasal passages for the treatment of CRS.
Product Name : LYR-220
Product Type : Steroid
Upfront Cash : Inapplicable
December 09, 2023
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYR-210 (mometasone furoate) is a bioresorbable nasal implant which is intended to deliver up to six months of continuous, proven anti-inflammatory therapy, mometasone furoate, to the sinonasal passages to treat chronic rhinosinusitis (CRS).
Product Name : LYR-210
Product Type : Steroid
Upfront Cash : Inapplicable
August 29, 2023
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYR-220 (mometasone furoate) is a bioresorbable, polymetric matrix that is designed to deliver six months of continuous anti-inflammatory medication (7500µg MF) to the sinonasal passages for the treatment of CRS.
Product Name : LYR-220
Product Type : Steroid
Upfront Cash : Inapplicable
June 02, 2023
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYR-210 is a bioresorbable nasal implant which is intended to deliver up to six months of continuous, proven anti-inflammatory therapy, mometasone furoate, to the sinonasal passages to treat chronic rhinosinusitis (CRS).
Product Name : LYR-210
Product Type : Steroid
Upfront Cash : Inapplicable
April 25, 2023
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Perceptive Advisors
Deal Size : $50.0 million
Deal Type : Private Placement
Lyra Therapeutics Announces Closing of $50.0 Million Private Placement
Details : The financing will be used to complete company's pivotal clinical trials of LYR-210 (mometasone furoate), a bioresorbable nasal mesh, being developed in Phase 3 for chronic rhinosinusitis (CRS) patients.
Product Name : LYR-210
Product Type : Steroid
Upfront Cash : Undisclosed
January 06, 2023
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Perceptive Advisors
Deal Size : $50.0 million
Deal Type : Private Placement
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYR-220 (mometasone furoate) is designed as a non-invasive alternative to repeat sinus surgery for CRS patients who have an enlarged nasal cavity due to sinus surgery but continue to require treatment to manage CRS. symptoms.
Product Name : LYR-220
Product Type : Steroid
Upfront Cash : Inapplicable
September 13, 2022
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYR-210 (mometasone furoate) is an investigational product candidate that utilizes Lyra's proprietary XTreoTM platform to enable six months of local, intra-nasal, anti-inflammatory therapy from a single treatment for CRS.
Product Name : LYR-210
Product Type : Steroid
Upfront Cash : Inapplicable
August 09, 2022
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The positive data for LANTERN Phase 2 results for LYR-210 treated subjects reported dose-dependent global symptom improvement, achieving statistical significance (p<0.05) in each SNOT-22 subdomain compared to control at week 24.
Product Name : LYR-210
Product Type : Steroid
Upfront Cash : Inapplicable
April 30, 2022
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable